CA2163640A1 - Stable copper (i) complexes and their use as active therapeutic substances - Google Patents

Stable copper (i) complexes and their use as active therapeutic substances

Info

Publication number
CA2163640A1
CA2163640A1 CA002163640A CA2163640A CA2163640A1 CA 2163640 A1 CA2163640 A1 CA 2163640A1 CA 002163640 A CA002163640 A CA 002163640A CA 2163640 A CA2163640 A CA 2163640A CA 2163640 A1 CA2163640 A1 CA 2163640A1
Authority
CA
Canada
Prior art keywords
copper
complex
complexes
bcds
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002163640A
Other languages
English (en)
French (fr)
Inventor
Alexander J. Pallenberg
Andrew Branca
Thomas M. Marschner
Leonard M. Patt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procyte Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2163640A1 publication Critical patent/CA2163640A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002163640A 1993-06-02 1994-06-02 Stable copper (i) complexes and their use as active therapeutic substances Abandoned CA2163640A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7144093A 1993-06-02 1993-06-02
US08/071,440 1993-06-02

Publications (1)

Publication Number Publication Date
CA2163640A1 true CA2163640A1 (en) 1994-12-08

Family

ID=22101339

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002163640A Abandoned CA2163640A1 (en) 1993-06-02 1994-06-02 Stable copper (i) complexes and their use as active therapeutic substances

Country Status (8)

Country Link
EP (1) EP0701439A1 (xx)
JP (1) JPH08511006A (xx)
AU (1) AU7051794A (xx)
CA (1) CA2163640A1 (xx)
OA (1) OA10198A (xx)
TW (1) TW239077B (xx)
WO (1) WO1994027594A2 (xx)
ZA (1) ZA943857B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562854B2 (en) 1994-12-14 2003-05-13 Axys Pharmaceuticals, Inc. Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders
AU6274896A (en) * 1995-06-06 1996-12-24 Procyte Corporation Stable copper(i) complexes as active therapeutic substances
US5637311A (en) * 1995-06-29 1997-06-10 Procyte Corporation Zinc(II) complexes and methods related thereto
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US6150379A (en) * 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD FOR TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF AN ACUTE INCREASE OF HYPERGLYCEMIA AND / OR ACUTE INCREASE IN FREE FATTY ACID FLUID
BRPI0613824A2 (pt) 2005-06-20 2011-02-15 Dynamiclear Pty Ltd composição para tratamento de lesões da pele
WO2010026730A1 (ja) * 2008-09-03 2010-03-11 Nbc株式会社 抗ウイルス剤
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
TWI580787B (zh) * 2012-12-28 2017-05-01 簡宏堅 重組蛋白質、含有該重組蛋白質之醫藥組成物及該重組蛋白質之製備方法
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
KR20210087893A (ko) * 2018-06-04 2021-07-13 케미스트리알엑스. 모발 성장 촉진을 위한 국소 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
JPS6259213A (ja) * 1985-09-10 1987-03-14 Eisai Co Ltd ス−パ−オキサイド除去剤

Also Published As

Publication number Publication date
WO1994027594A2 (en) 1994-12-08
TW239077B (xx) 1995-01-21
JPH08511006A (ja) 1996-11-19
WO1994027594A3 (en) 1995-04-27
ZA943857B (en) 1995-02-01
EP0701439A1 (en) 1996-03-20
OA10198A (en) 1996-12-18
AU7051794A (en) 1994-12-20

Similar Documents

Publication Publication Date Title
AU735127B2 (en) Purine inhibitor of protein kinases, G proteins and polymerases
Balzarini et al. 9-(2-Phosphonylmethoxyethyl) adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys
Benzaria et al. Synthesis, in vitro antiviral evaluation, and stability studies of bis (S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy) ethyl] adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability
Josephson et al. Isolation of a potent (Na-K) stimulated ATPase inhibitor from striated muscle
CA2163640A1 (en) Stable copper (i) complexes and their use as active therapeutic substances
Meier et al. cyclo Sal-Pronucleotides of 2 ‘-Fluoro-ara-and 2 ‘-Fluoro-ribo-2 ‘, 3 ‘-dideoxyadenosine as a Strategy to Bypass a Metabolic Blockade
Meier et al. cyclo Sal-Pronucleotides of 2 ‘, 3 ‘-Dideoxyadenosine and 2 ‘, 3 ‘-Dideoxy-2 ‘, 3 ‘-didehydroadenosine: Synthesis and Antiviral Evaluation of a Highly Efficient Nucleotide Delivery System
EP1079826B1 (en) Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
MXPA01001893A (es) Derivados de quinazolina.
US6187775B1 (en) Acridone-derived compounds useful as antineoplastic and antiretroviral agents
US5637311A (en) Zinc(II) complexes and methods related thereto
Levinson Inhibition of Viruses, Tumors, and Pathogenic Microorganisms by Isatin β-Thiosemicarbazone and Other Thiosemicarbazones
Rosowsky et al. Methotrexate analogs. 19. Replacement of the glutamate side-chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity
Hostetler et al. Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro
WO1996039144A1 (en) Stable copper(i) complexes as active therapeutic substances
US20110144192A1 (en) Method for modulating or controlling sodium channel current by reactive oxygen species (ROS) originating from mitochondria
Sayre et al. Dopaminergic neurotoxicity in vivo and inhibition of mitochondrial respiration in vitro by possible endogenous pyridinium‐like substances
Zhang et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase activity by dopachrome analogs
Hamon et al. Effect of antineoplastic and cytotoxic Mannich bases derived from conjugated styryl ketones on mitochondrial respiration in rat liver cells
Van Gelder et al. Inhibition of intestinal metabolism of the antiviral ester prodrug bis (POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study
Tedde et al. Effects of 2′-deoxycoformycin infusion on mouse adenosine deaminase
CN103183722B (zh) 一种乙二醛酶i抑制剂及其制备方法和医药用途
US5077279A (en) 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
Satoh et al. Inhibition of Na+, K+-ATPase by the extract of Stephania cephararantha Hayata and bisbenzylisoquinoline alkaloid cycleanine, a major constituent
Mehta et al. Relationship of skin target site free drug concentration (C*) to the in vivo efficacy: an extensive evaluation of the predictive value of the C* concept using acyclovir as a model drug

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 19990602